The amplification units in human tumors containing amplified myc genes were examined. The amplifilcation unit in all cases consisted of a large genomic region coamplified with the coding region of the myc genes themselves. In eight independent neuroblastomas containing N-myc amplifications, the amplification unit was estimated to be 290 to 430 kilobases. This amplification unit was highly conserved among the different neuroblastomas, with some neuroblastomas containing almost identical units. In contrast, five tumor cell lines containing c-myc amplifications exhibited amplification units that were more variable in size (90 to 300 kilobases) and sequence content; at least three different patterns of c-myc amplification units could be discerned.
It has been shown that increased levels of normal cellular oncogene products are capable of transforming cells (1, 2) . Gene amplification provides a potent mechanism for increasing the amount of a normal cellular oncogene product (reviewed in refs. [3] [4] [5] . Amplification of various oncogenes has been reported in a variety of human tumors or cell lines derived from human tumors. These reports have included amplification of c-erbB in brain tumors and a squamous cell carcinoma (6) (7) (8) , c-abl in leukemia (9, 10) , c-myb in colon cancer and leukemia (11, 12) , N-myc in neuroblastomas and retinoblastomas (13) (14) (15) (16) , and c-myc in several types of tumors (17) (18) (19) (20) (21) . Despite the fact that amplified oncogenes have occurred in this wide variety of neoplasms, little is known about the mechanism of oncogene amplification or the structure of their amplification units.
At the chromosomal level, the amplified oncogenes are contained within double minute chromosomes (DM) or homogeneously staining regions (HSR) (reviewed in refs. [3] [4] [5] . DM and HSR also occur in drug resistant cell lines. In such cases, it has been shown that the genes conferring drug resistance are amplified within a large domain of DNA that includes 100 to 1000 kilobases (kb) of sequences flanking the drug resistance genes themselves (22) (23) (24) (25) (26) . The amplified gene and coamplified flanking sequences form the amplification unit. An understanding of the structure of the amplification unit is essential to delineating the mechanism of amplification.
We have now partially characterized the amplification units in eight human neuroblastomas containing amplified N-myc genes and five human cell lines containing amplified c-myc genes. In both cases, large domains of coamplified sequences accompanied the amplification of the coding region of the oncogene. The N-myc amplification unit was approximately 290 to 430 kb in length and was highly conserved among neuroblastomas from eight different patients. The size of the c-myc amplification unit was much more variable, ranging from 90 to 300 kb. The patterns of amplified sequences indicated that at least three different c-myc amplification units were represented by the five cell lines studied. These results with oncogene amplification units are compared with the amplification units in drug resistant cell lines.
MATERIALS AND METHODS
Preparation of DNA. The neuroblastoma tumors were obtained as fresh tissues at surgery from untreated patients using approved institutional and National Institutes of Health guidelines for patient material (33) . Cell lines examined included NGP, derived from a neuroblastoma (15) ; NCI-H82 and NCl-N417, derived from small cell carcinomas ofthe lung (21) ; COLO 320DM (line with DM), derived from a colon tumor (17) ; HL-60, derived from a promyelocytic leukemia (18, 19) , and SF188, derived from a glioblastoma multiform (27) . DNA was purified from cell lines or tumors using proteinase K digestion followed by phenol/chloroform extraction and ethanol precipitation (28) .
Assay for Amplified Restriction Fragments. Amplified DNA fragments were detected using a slight modification of a technique described by Roninson (29) . DNA (10 ,ug) IlTo whom correspondence should be addressed.
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Southern transfer and nitrocellulose filter hybridization were performed as described (30, 31) . The probe used for c-myc was a 5.5-kb BamHI fragment of the murine myc gene provided by Kirsch et al. (32) . The probe used for N-myc was a 1.0-kb EcoRI-BamHI fragment ofpNb-1 (15) obtained from ONCOR (Bethesda, MD).
RESULTS
To characterize the amplification units of myc genes, we employed a technique developed by Roninson (29) . After cleavage with an appropriate restriction endonuclease, 0.2 ,ug of the DNA was end labeled with [a-32P]dCTP using T4 DNA polymerase. The labeled DNA was mixed with 9.8 ,g of unlabeled driver DNA and separated by electrophoresis through an agarose gel. While in the gel, the DNA was denatured by alkaline treatment and renatured under conditions where only normally repeated or amplified restriction fragments that are present 20 times or more per haploid genome will reanneal. Single-stranded DNA was degraded with S1 nuclease and eluted by diffusion. The DNA fragments remaining in the gel were visualized by autoradiography. After this treatment, DNA isolated from normal cells is represented by a small number of distinct fragments that correspond to normally repeated sequences (e.g., satellite DNA and mitochondrial DNA sequences). DNA isolated from cells with specific gene amplifications is characterized by additional amplified fragments. It is possible that amplified restriction fragments present in only a subset of the amplification units would not be detected in our assay. Therefore, the amplified fragments detected by this assay represent the core of the amplification unit (i.e., those sequences present in the majority of the amplification units within any one tumor).
The data obtained by applying this technique to eight human neuroblastomas, known to have 150-to 300-fold amplifications of the N-myc gene (33) (33) . NGP is a cell line with an HSR containing amplified N-myc (15) . *Determined by summing the sizes of the additional amplified fragments (i.e., those not present in DNA from normal cells).
tDetermined by summing the sizes of the additional amplified fragments detected using N3 DNA as tracer.
tDetermined by dividing the N3 common amplification unit (t) by the total amplification unit size (*).
patterns for different tumors were quite similar. However, it was possible that comigrating fragments were not identical. A more precise determination of conserved sequences could be determined by mixing labeled tracer DNA from one sample with unlabeled driver DNA from another sample (29) . Under the conditions employed for such a mixing experiment, a DNA fragment must be amplified in both the tracer DNA and the driver DNA for the fragment to remain and be visualized by autoradiography. Thus mixing experiments provide a convenient method for determining if amplified restriction fragments of one tumor are also amplified in another tumor without cloning the individual fragments. A mixing experiment was performed to determine the extent of the common amplified fragments among the different neuroblastomas. Tracer DNA from neuroblastoma N3 was individually mixed with driver DNA from each of the eight neuroblastomas, from one normal tissue, and from one cell line containing amplified c-myc genes (Fig. 1B ). An average of 53 restriction fragments from neuroblastoma N3 were amplified in the other neuroblastomas; these fragments represented from 290 to 370 kb of common amplified sequences (Table 1 ). The sample containing the amplified c-myc gene (C3) did not exhibit any fragments in the N3 mixing experiment not present in the normal control (L). Analysis of the data in Fig. 1A and B revealed that an average of 93% of the total amplification unit of any of the other seven neuroblastomas was common to neuroblastoma N3 (Table 1) . A similar degree of conservation was observed when neuroblastoma N2 was used as the tracer in a mixing experiment (data not shown). Hence, these results suggested a great similarity between the amplification units in different neuroblastomas.
We next analyzed five cell lines derived from human lung, brain, colon, or hematopoietic cancers that had been demonstrated to have an -50-fold amplification ofthe c-myc gene (17-19, 21, 27 ). There were 17-to 48-additional amplified fragments of DNA from these cell lines, corresponding to domain sizes of from 90 to 300 kb ( Fig. 2A, Table 2 ). The patterns of amplified fragments did not appear to be as conserved as in the neuroblastomas. Indeed, when C4 was used as tracer DNA in a mixing experiment, only a minority of the amplified restriction fragments (4 to 10 of 39) was common to the other cell lines (Fig. 2B, Table 2 ). When C1 was used as a tracer in a second mixing experiment, the majority of C1 fragments was common to C2 and C3 (24 and 18 of 31, respectively) while C4 and C5 exhibited only 4 and 7 fragments common to C1, respectively ( Fig. 2C and Table  2 ). When C5 was used as a tracer, 4 fragments of 17 were amplified in each of the other cell lines (Table 2 ). There were only two fragments (of 10.5 and 3.6 kb) that were found to be amplified in all five cell lines in each of the mixing experiments. In addition, Southern blot analysis revealed a third HindIII fragment of 9.9 kb, containing the c-myc gene itself, which was not detected with the Roninson technique using HindIII, because it comigrated with a normally repeated 9.7-kb band derived from mitochondria. This 9.9-kb c-myc fragment was amplified in all the cell lines except C2, in which the amplified c-myc gene was contained within rearranged 12-and 15-kb fragments (K.W.K., unpublished data).
Hence, a 24-kb region was commonly amplified in the five cell lines studied but there appeared to be at least three distinct domains of DNA flanking this core that were coamplified with the c-myc gene in different cell lines. C1, C2, and C3 were found to have significant parts of their amplification units in common (greater than 50%) whereas C4 and C5 each had relatively distinct amplification units. These patterns did not correlate with tissue type (since C3 and C4 were both small-cell lung carcinoma lines) nor with the presence of HSR or DM (Cl, C2, and C5 had DM while C3 and C4 had HSR). We also examined the amplification units in DNA from two samples of cell line C4 that had been independently passaged for several hundred generations in two different laboratories. As shown in Fig. 2 , the amplification patterns observed in these two samples were virtually identical suggesting that, in at least this case, the c-myc amplification unit was quite stable.
DISCUSSION
The studies described above characterize the amplification units of c-myc and N-myc oncogenes by two important criteria, the size of the amplification unit and the degree of variability of the amplification unit arising in different tumors. Both of these parameters may eventually be helpful in delineating the molecular events that lead to amplification. It Amplified restriction fragments contained in both the C4 DNA and the driver DNA were visualized by autoradiography. (C) Autoradiograph of mixing experiment using C1 as tracer. Labeled C1 DNA was mixed with driver DNA from normal tissue (L), N4, itself, or the other cell lines and assessed for amplified sequences. N4 refers to a neuroblastoma with amplified N-myc (see Fig. 1 ). Amplified restriction fragments contained in both the C1 and the driver DNA were visualized by autoradiography. C1  31  190  7  40  21  31  190  100  4  25  13  C2  48  300  10  60  20  24  150  50  4  25  8  C3  19  120  6  30  25  18  110  92  4  25  21  C4  39  230  39  230  100  7  40  17  4  30  13  C5  17  90  4  30  33  4  30  33  17  90  100 C1, C2, C3, C4, and C5 are cell lines SF 188 (brain Lumor), COLO 320-DM (colon tumor), NCI-H82 (small cell carcinoma of lung), NCl-N417
;,nall cell carcinoma of lung), and HL-60 (promyelocytic leukemia), respectively.
Determined by summing the sizes of the additional amplified fragments.
Determined by summing the sizes of the additional amplified fragments detected using specified DNA as tracer.
tDetermined by dividing the specified common amplification unit (t) by the total amplification unit size (*).
determined by our analysis represents an estimate of the actual size and, like any estimate, is subject to certain limitations. The nature of our technique probably provides an underestimate of the actual size for three reasons. First, restriction fragments of small size were not represented in the gels we used, which provided maximum resolution for fragments greater than 2.5 kb. To confirm this possibility, we performed similar analyses by using higher percentage agarose gels to detect smaller fragments and found that these smaller fragments comprised less than 5% of the measured amplification unit size. Second, despite the high resolution obtained, it is possible that fragments of similar size would not be resolved. To account for this possibility, fragments that appeared to be doublets (as determined by doubled density) were counted accordingly, to obtain the values in Tables 1 and 2 . Finally any restriction fragments present in only a subset of the amplification units would probably not be detected in our assay. Therefore, our studies concern the core of the amplification unit, and these studies do not rule out the presence in any individual tumor of minor variants of the amplification unit or heterogeneity outside this core. Similarly, our comparison of amplification units between different tumors in reality represents comparisons between amplification unit cores. Our estimate of90 to 430 kb for the size of the amplification unit of N-myc and c-myc in human tumors is similar to the range of 100-1000 kb estimated by others for the amplification unit of the dihydrofolate reductase (DHFR) gene and CAD gene in drug resistant rodent lines (24, 25, 34, 35) . The sizes of these amplification units are clearly larger than that necessary to encode the presumptive target gene (e.g., N-myc, c-myc, DHFR, or CAD). It is possible that the amplification unit is similar or identical to a replication unit or replicon, as has been suggested (3, 4, 36, 37) . Our estimate for the amplification unit in neuroblastoma (290 to 430 kb) is much less than the estimate of3000 kb obtained for the N-myc amplification unit in the human neuroblastoma cell line IMR-32, which is the only available estimate for the amplification unit of an oncogene (38) . This discrepancy can be attributed to several factors. First, the differences may reflect differences in the methods used to estimate the amplification unit. The estimate of 3000 kb was obtained by dividing the total DNA content of the HSR by the repetition factor of the amplification unit. Hence, this estimate critically depends on the accuracy of the values obtained for the DNA content of the HSR and the repetition frequency of the amplification unit. Second, this discrepancy may result from differences in the amplification unit in IMR-32 and those of other neuroblastomas. Indeed, IMR-32 appears to contain an unusual amplification unit since only 3 of 11 probes that were amplified in IMR-32 were amplified in any of 24 other neuroblastomas with an amplified N-myc (39) . The IMR-32 specific amplified sequences were found to be normally located on chromosome 2 in a locus distinct from that of N-myc.
The data obtained from the mixing experiment indicates that the N-myc amplification units are very similar in neuroblastomas from different patients whereas the c-myc amplification units were more variable in the five cell lines examined. It is of interest to compare these results on oncogene containing amplification units with those observed with amplified drug resistance genes in rodent cells. Those studies have shown, (with one exception, ref. 25 ) that the amplified sequences were highly variable from one drug resistant cell line to another, with only a srr~all percentage of restriction fragments commonly amplified (22, 23, 40) . Our results with the N-myc amplification units in neuroblastoma tumors were clearly different from most of the drug resistance genes studies because the majority of amplified restriction fragments identified were present in all eight neuroblastoma lines examined. The fact that the neuroblastoma tumors from four individuals (N3, N5, N7, and N8) had almost identical amplification units is consistent with a discrete common chromosomal domain as the precursor of the amplification unit. Alternatively unequal crossing over and gene conversion, which have the effect of homogenizing repeatedsequence arrays, may be contributing to the homogeneity reported here. In contrast, the c-myc amplification units were as variable as those described in drug resistant cell lines. One possible explanation for the difference between the results with the N-myc amplification units and the c-myc amplification units is that the N-myc amplification unit was studied in tumors while the c-myc amplification unit was studied in cell lines. All previous studies of amplification units utilized cell lines. However, our study ofthe neuroblastoma cell line NGP has shown amplification units quite similar to those obtained for the primary neuroblastomas (Table 1) . Therefore, the constancy of the N-myc amplification units and the variability of the c-myc amplification units may reflect inherent differences in their structure or mechanisms responsible for their amplification. Selective pressures such as chemotherapy, environment, and coamplified genes could also play a role in shaping the different amplification units. Indeed, it has been reported that expressed genes other than N-myc are amplified in cell lines containing amplified N-myc genes (41 
